Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
-
Edmund Richardson Wins Baillie Gifford Prize for 'Alexander' Biography
-
Pakistan Demands Grant-Based Climate Finance at COP31 to Avoid Debt Trap
-
BYD Drops Rotating Screens in New Models Due to Tech Limits
-
E Pellicci Pop-Up at Selfridges Brings Back Nostalgic School Cake
-
Ryanair Flight from Rome Makes Emergency Landing in Lisbon After Bomb Threat
-
Coronation Street's Debbie Webster Steps Down as Dementia Storyline Intensifies
-
Maltese President Visits London Hospital to Support Families Facing Medical Care Challenges
-
Globa Terra Acquisition Corporation Reports Encouraging Investor Support Ahead of November 9 Extension Vote
-
Gladstone Investment Corporation Acquires Majority Stake in McFarlane Toys
-
RenX Microtec Mill Is Built; Power and Commissioning Are Next
-
Watermelon Z Strain Guide Clarifies Conflicting Breeder Information and Genetic Lineage
-
MADE in America is Great Again; SMX has the Proof
-
Patterson-UTI Reports Drilling Activity for October 2026
-
Green Leaf Innovations (OTC PINK:GRLF) Reports 51% Sequential Revenue Growth and 115% Net Income Increase in Q2 2026
-
IRS Reports a Record $5.6 Trillion Collected in FY 2026 - Clear Start Tax Explains What Record Collection Performance Means for People Who Still Owe
-
Ambee and meteoblue Announce Partnership on Climate Risk and Resilience Data
-
RAEK Unveils New Designs for Creator Vault, Its First Private AI Appliance
-
21- and 23-Year-Old Co-Founders Build Multi-Million Dollar Global BPO in Under 18 Months
-
Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
-
Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
-
BioScience Health Innovations, Inc. Announces Its Subsidiary Vitalcore Research has Executed Master Distribution Agreement with Rule Imports
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 06
-
ACE Survey Finds 35% of Adults Wouldn't Have Returned to School Without Online Options
-
New Jobs & Big Deals: Forman Mills Opens Ninth Illinois Location
-
Pebble Beach Concours d'Elegance Reaches $50 Million in Charitable Giving
-
AI Agents Are Joining the Workforce - Living Security Says Preemptive Security Starts With Human and Agent Risk Visibility
-
Nathan Charnes Elected 45th President of the PGA of America
-
Valsoft's TAG Software Group Enters the Content Operations Market with the Acquisition of Chalco
-
OSR Health Exercises $15 Million VXM01 Equity Option, Elects Settlement Through Staged Convertible Notes
-
Wipeboard Launches Ghost.Wipeboard.io, a Case Management Workspace Built for Paranormal Investigation Teams
-
Prometheus Laboratories Presents Research Showing Superior Performance of MASH Precis Fibrosis Score in Identifying Treatment-Eligible Patients
-
Eylsia Nicolas Returns to Her Signature Sound as "Where or When" Debuts at #4 on the Groover U.S. Rock Charts
-
Plastic Recycling has a New Passport; SMX is the Stamp
-
Stagwell Media Names Kate Richling as Chief Brand and Communications Officer
-
Maxon Expands Creative Possibilities with New Touch and Spatial Experiences in Cinema 4D and ZBrush for Apple Products
-
SMX: Plastic Recycling is no Longer a Favor; it's a Must
-
Record Seven Muslim Americans Elected to US Congress in Historic Midterm Shift
-
Luxembourg Minister Warns Trump of 'Lame Duck' Risk Amid Global Updates
-
Samsung Leads Global DRAM Market as SK Hynix Gains Share
-
South Korea Proposes Fourth Delay of Cryptocurrency Gains Tax to 2029
-
Kakao Details Spinoff Plan to Monetize AI Through KakaoTalk
-
ASIC Fines Mona Museum Owner's Company for Late Financial Report
-
Business Leaders Criticize Productivity Commission Inquiry Scope
Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company identifies and advances therapeutic programs addressing significant unmet medical needs.
The Company announces that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be in Miami, Florida during the upcoming Jefferies and Leerink Healthcare Conferences and will be available for meetings with investors, pharmaceutical companies, and organizations interested in learning more about the Company and its programs.
Lobe acquires preclinical and early-stage therapeutic assets and places them within focused subsidiary entities. Each program follows a defined development and funding structure designed to support advancement through regulatory and clinical milestones. The Company's approach includes formulation development, intellectual property protection, and engagement with regulatory authorities as programs advance through clinical evaluation and value-inflection points in a cost-efficient manner.
Lobe is currently advancing two patented assets through this subsidiary approach: L‑130, targeting chronic cluster headache, and S‑100, focused on sickle cell disease. Additional programs under evaluation include therapies for substance use disorder and other neurological indications.
Organizations interested in arranging a meeting with Dr. Sancilio while he is in Miami may contact the Company by email at [email protected] to schedule an appointment.
About Lobe Sciences Ltd.
Lobe Sciences Ltd. is a biopharmaceutical company advancing programs in diseases with unmet medical needs. The Company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Applied Lipid Technologies, Inc. (formerly Altemia, Inc.).
About Cynaptec Pharmaceuticals, Inc.
Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L‑130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders. Cynaptec is 64% owned by Lobe.
About L‑130 (psilocin mucate)
L‑130 is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy. Conventional psilocin has historically been difficult to develop as a pharmaceutical due to stability limitations; the L‑130 compound was developed to address these challenges.
For Further Information
Dr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email: [email protected]
Phone: +1 (949) 505-5623
Website: www.lobesciences.com
Cautionary Statement Regarding Forward-Looking Information
This news release may include certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements other than statements of historical facts may constitute forward-looking information. Forward-looking information is based on assumptions and is subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update forward-looking information except as required by applicable securities laws.
SOURCE: Lobe Sciences Ltd.
View the original press release on ACCESS Newswire
D.Cunningha--AMWN